Several studies documented an association between metabolic syndrome (MetS) and left ventricular (LV) hypertrophy. However, only in a few of these studies the impact of MetS on left ventricular mass (LVM) was separately analysed by gender, with conflicting results. The aim of our study was to verify, in a wide sample of essential hypertensive patients, the influence of gender, if any, on the relationship between MetS and LVM. We enrolled 475 non-diabetic subjects (mean age: 46 ± 11 years), with mild-to-moderate essential hypertension, of whom 40% had MetS, defined on the basis of Adult Treatment Panel III (ATPIII) criteria. All the patients underwent a 24-h ambulatory blood pressure monitoring and an echocardiogram. LVM indexed for height 2.7 (LVMH 2.7 ) was significantly (Po0.001) higher in women with MetS (n ¼ 83) than in those without it (n ¼ 97; 54 ± 17 vs 42±11 g m
Introduction
Although the definition and nosological significance of metabolic syndrome (MetS) has been the subject of recent debate, 1, 2 it is increasingly recognized as an independent predictor of cardiovascular (CV) diseases in general population and also in subjects with high blood pressure (BP), even in the absence of diabetes. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] In some studies the CV morbidity and mortality risk associated with MetS has been examined separately in men and women and sometimes the prognostic impact of MetS was found to be higher in the female sex. 3, 4 The development of asymptomatic structural and functional abnormalities at cardiac level in hypertensive patients with MetS may partially explain the occurrence of CV complications in this population. 6, 12 Left ventricular hypertrophy (LVH), detected either by electrocardiography or echocardiography, is a strong predictor of myocardial infarction, cardiac sudden death, congestive heart failure and stroke. 13, 14 Subjects with left ventricular mass (LVM) in the upper normal range already have increased risk for CV events. 15 MetS has been associated with an increased LVM in recent reports conducted in hypertensive patients and in general population, 6, 7, 12, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] independently of various confounding factors, such as BP values and age. However, only in a few of these studies the impact of MetS on LVM was separately analysed by gender, with conflicting results. 6, 17, 24, 25 Therefore, the aim of our study was to verify, in a wide sample of non-diabetic hypertensive patients without CV and renal diseases, the influence of gender, if any, on the relationship between MetS and LVM.
Methods
The population of this cross-sectional study was selected from 536 hypertensive Caucasian patients consecutively attending our hypertension centre. Most of them had been referred to our institution by their general practitioners for specialist advice.
The exclusion criteria were: secondary or malignant hypertension, heart failure, positive history or clinical signs of ischaemic heart disease, cerebrovascular disease, renal insufficiency, defined by a creatinine clearance rate o60 per ml À1 min À1 per 1.73 m À2 (estimated by the Cockcroft-Gault formula), overt proteinuria, major non-CV diseases, dyslipidaemia requiring pharmacological treatment, and known diabetes or fasting glycaemia X126 mg per 100 ml. A total of 10 subjects met these criteria and therefore were not enrolled.
Of the remaining individuals 51 were also excluded, because of sub-optimal echocardiographic tracings. Hence, the final statistical analysis involved 475 patients.
Before entering the study, 227 hypertensive subjects had been pharmacologically treated. These patients were studied at least 2 weeks after the discontinuation of all anti-hypertensive drugs.
All the participants to this study may be considered as sedentary subjects. Persons who reported smoking cigarettes regularly during the past years were considered current smokers.
Informed consent was obtained from each patient. The study protocol, which conforms to the ethical guidelines of the Declaration of Helsinki, was approved by the local review board.
Study design
In all subjects careful clinical history and physical examination were performed. Body weight, height and waist circumference were measured by a nurse. After the period of pharmacological washout, clinic BP was recorded by a doctor, in the non-dominant arm using the auscultatory method with a mercury sphygmomanometer and appropriated cuff for arm diameter, following the 2007 guidelines of the European Society of Hypertension. 26 Three consecutive measurements were taken at 2-min intervals and averaged.
The following morning, after an overnight fast of at least 12 h, blood samples were drawn to perform routine blood chemistry.
Furthermore, 24-h ambulatory BP-monitoring (ABPM) and echocardiographic study were carried out.
Measurements
Determination of routine biochemical parameters was performed with standard techniques by using an autoanalyser (Hitachi system 911; Boehringer, Mannheim, Germany). Low-density lipoprotein cholesterol (LDL) was calculated by the Friedwald formula.
MetS was defined in line with the criteria laid down in the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP-ATPIII), with the minor modifications recommended by the 2005 American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. 2 Therefore, individuals were classified as having the MetS if they had, in addition of hypertension, two or more of the following abnormalities: high-density lipoprotein (HDL) o40 mg per 100 ml in men or 50 mg per 100 ml in women; fasting glucose between 100 and 125 mg per 100 ml; triglycerides 4150 mg per 100 ml; and waist circumference 4102 cm in men or 488 cm in women. M-mode measurements were taken at end diastole and end systole in line with the American Society of Echocardiography (ASE) recommendations. 27 Only those frames with optimal visualization of interfaces and showing simultaneous visualization of septum, left ventricular (LV) internal diameter and posterior wall were used for readings. Myocardial relative wall thickness (RWT) was calculated as twice of posterior wall in diastole divided by internal diameter, and was used as an estimate of LV geometry.
LVM was determined using the ASE corrected cube formula:
It was indexed by both body surface area (BSA; LVMI) and by height elevated by a power of 2.7, as suggested by de Simone et al., 29 in order to provide a more stringent allowance for obesity (LVMH 2.7 ). A cutoff point of 51 g m À2.7 in either gender was set to separate normal from LVH, because this partition value is supported by prognostic evidence. 30 LVH was defined also as LVMI X125 g m À2 for men and X110 g m À2 for women, as suggested by the 2007 guidelines of the European Society of Hypertension. 26 Echocardiographic data are expressed as the average of five consecutive cardiac cycles. Images were read blindly by a single cardiologist, unaware of the patient's clinical characteristics.
In our laboratory, the mean intra-observer variability for LVM was 8.6%.
Statistics
The study population was separated into two groups of male and female subjects. Each group was subdivided in patients with and without MetS.
We separated also the study population in sexspecific tertiles of age (division points for women: 43 and 52 years; for men: 40 and 50 years) and of 24-h systolic BP (SBP, division points for women: 127 and 137 mm Hg; for men: 130 and 140 mm Hg). Continuous variables were given as means±s.d.
Differences between subgroups with and without MetS were evaluated using the independent-sample Student's t-test for continuous variables and the w 2 -test, with Yates' correction, for the categorical variables.
To investigate in either gender the association between MetS and LVH, multiple logistic regression analyses were performed by calculating odds ratio (OR) and their 95% confidence limits (CIs), after adjustment for age, 24-h SBP, duration of hypertension and previous pharmacological antihypertensive treatment.
The effects of sex and MetS on LVM index (LVMH 2.7 and LVMI) were assessed by a two-way analysis of variance, initially without any adjustments and then with adjustment for potential confounders. Interaction between sex and MetS was formally tested by assessing the significance of the multiplicative two-way interaction term 'gender Â MetS' along with the main effects of sex and MetS.
Linear multiple regression analysis was used to explore the independent determinants of LVMH 2.7 in both sexes. A backward stepwise procedure was used, with a ¼ 0.15 as the cutoff for entry or removal of variables, which is the default value of the SYSTAT statistical package. Initially, MetS and previous pharmacological anti-hypertensive therapy (included as a dummy variables), age, duration of hypertension, 24-h SBP, 24-h heart rate and duration of hypertension, were considered in order to build the multiple regression models. Subsequently we ran the models again, after adding body mass index (BMI, glycaemia and total cholesterol, along with those factors associated with LVMH 2.7 in the first model.
We cannot exclude that the high degree of colinearity between MetS, BMI and indexed LVM may potentially lead to inaccurate estimates of the regression coefficients in the above described multiple regression models. For this reason in the whole study population we also tested an additional multivariate regression model in which non-indexed LVM was considered as dependent variable and age, gender, previous anti-hypertensive therapy, weight, height, 24-h SBP, 24-h heart rate, duration of hypertension, glycaemia, total cholesterol, MetS and the interaction term 'gender Â MetS' were included as explanatory variables.
The null hypothesis was rejected at a two-tailed o0.05.
The statistical analyses were performed using the SYSTAT DATA software package, version 12 (Systat, San Jose, CA, USA).
Results
Mean age of the study population was 46 ± 11 years. Men were 295 (56%). Table 1 summarizes demographic and clinical data of the overall population, subdivided according to gender and to the presence or the absence of MetS. Overall prevalence of MetS was 40%.
Both male and female hypertensive patients with MetS were older and had greater BMI when compared to those without MetS.
Whereas clinic SBP was higher in both sexes in the subgroup with MetS, 24-h SBP was greater only in the subgroup of men with MetS, in comparison to those without it.
Main echocardiographic parameters of the study population are reported in Table 2 . In the group of female subjects, participants with MetS exhibited significantly higher values of interventricular septum and posterior wall thickness, LV internal dimension and a greater LVM, either non-indexed or normalized for BSA or height 2.7 . Myocardial RWT did not differ between the two subgroups ( Table 2) .
In male gender slightly less pronounced differences, but equally significant, were observed in the two subgroups of hypertensive patients with and without MetS, regarding LVM, independently of the method used for indexation. Moreover, LV internal dimension did not differ between the two subgroups and the RWT was higher in men with MetS than in those without it (Table 2) .
Also in the subset of hypertensive patients never pharmacologically treated for high BP, LVMH 2.7 was higher in both women (50.2 ± 12.5 vs 37.4 ± 6.1; Po0.001) and men (47.1 ± 11.9 vs 39.4 ± 8.7; Po0.001) with MetS compared with their counterparts without it. Similar results were obtained when LVM was indexed by BSA (all Po0.005).
In the whole population, a two-factor analysis of variance (ANOVA) model disclosed a significant effect of MetS (F ¼ 60.5; Po0.001), but not of gender (F ¼ 0.64; P ¼ 0.42) on LVMH 2.7 . The analysis of the interaction term 'gender Â MetS' revealed no significant effect of sex on the association between MetS and LVMH 2.7 , both before (F ¼ 1.83; P ¼ 0.18) and after adjustment for age, previous pharmacological anti-hypertensive therapy, duration of hypertension and 24-h SBP (F ¼ 2.66; P ¼ 0.10).
When in the same two-factor ANOVA model the dependent variable LVMH 2.7 was replaced by LVMI, there was a significant effect of MetS (F ¼ 28.3; Po0.001) and of sex (F ¼ 7.1; P ¼ 0.008) on LVM indexed for BSA. The analysis of the interaction term 'gender Â MetS' showed again no significant effect of gender on the association between MetS and LVMI, both before (F ¼ 0.06; P ¼ 0.81) and after adjustment for age, previous pharmacological antihypertensive therapy, duration of hypertension and 24-h SBP (F ¼ 0.17; P ¼ 0.68).
When we separated the study population in tertiles of age and 24-h SBP we observed, in either gender, greater values of LVM indexed for height 2.7 , in each tertile (Figures 1 and 2 ) in subgroups with MetS than in those without MetS. Similar results were obtained when LVM was normalized for BSA (data not shown).
The prevalence of LVH, defined as LVMH 2.7 X51 g m À2.7 , was greater in male and female patients with MetS than in those without it (Figure 3) . Similar results were obtained when LVH was defined as LVMI X110 g m À2 in women and X125 g m À2 in men (17.8 vs 7.8% in women and 21.9 vs 11% in men; all Po0.01).
The chance of having a value of LVMH 2.7 X51 g m À2 , in subjects with MetS, remained significant, also taking into account age, 24-h SBP, duration of hypertension and previous anti-hypertensive therapy by multiple logistic regression analyses (OR ¼ 3.08, 95% CI: 1.47-6.47; P ¼ 0.003, in women and OR ¼ 2.01, 95% CI: 1.13-3.56; P ¼ 0.01, in men). 
This association between MetS and LVMH 2.7 was attenuated but remained statistically significant after further adjustment for BMI (in women
The inclusion in the multivariate model of clinic, instead of the 24-h ambulatory BP readings, did not significantly modify the results. The same was true when BMI was replaced by waist circumference.
In order to overcome the potential problems of multi-colinearity, in the overall population we tested an additional multivariate relationship between non-indexed LVM and MetS, independently from several confounding factors (see 'Statistics' section). Also in this model we obtained a statistical significant association between LVM and MetS (b ¼ 0.11, P ¼ 0.01), and the absence of a significant effect of gender on this association (F-test for the interaction term 'sex Â MetS' ¼ 0.12; P ¼ 0.73).
Discussion
In the present study hypertensive patients with MetS, defined in accordance with NCEP-ATPIII criteria, exhibited higher LVM either non-indexed or normalized by height elevated by a power of 2.7 or by BSA and greater prevalence of LVH, than subjects without MetS.
These differences were replicated also in the subset of hypertensive patients never pharmacolo- ), in hypertensive women and men with (grey bars) and without (white bars) metabolic syndrome, subdivided in sex-specific tertiles of 24-h systolic blood pressure (SBP). Data are presented as means þ s.e.m. *Po0.05; **Po0.01;^Po0.005;^^Po0.001. X51 g m À2.7 , in hypertensive women and men with (grey histograms) and without (white histograms) metabolic syndrome. The most relevant aspect of this study is that the association between MetS and LVM was observed in both sexes. Women with MetS had an increase in LVMH 2.7 and LVMI, respectively, by 27 and 16% compared to women without MetS. Slightly less pronounced (16 and 13%, respectively), but equally significant, differences were found in men.
Previous reports have shown that MetS is associated with elevated LVM, 6, 7, 12, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] but the potential influence of gender on MetS-related LVH is controversial. 6, 17, 24, 25 In a study conducted on 618 hypertensive patients a remarkable sex difference in the association between MetS and LVH was found; indeed, in that study, MetS was a strong determinant of LVM in women beyond the influence of body size and haemodynamic variables, whereas the relation was weaker and fully explained by the effect of confounding factors in men. 24 The authors, 24 which did not provide a biologically plausible mechanism of this sex-related different influence of Mets on LVM, concluded that their findings may contribute to explain the greater prognostic impact of MetS observed in women than in men in some, but not all, studies. [3] [4] [5] [6] At variance with these findings, in the Atherosclerosis Risk in Communities study, conducted in a group of 1572 black adults, LVM indexed by height gradually increased with increasing number of MetS components, in the same way in both sexes. 17 Associations were diminished slightly by adjustment for smoking, alcohol intake and education. Interestingly, additional adjustment for waist circumference resulted in some attenuation, but associations remained statistically significant. 17 Being the population of this study constituted by black people, these results may not be extended to other populations, in regard to the documented greater prevalence of metabolic disorders and cardiac hypertrophy of this race. 17 However, similar conclusions were reported in the PAMELA (Pressioni Arteriose Monitorate E Loro Associazioni) study, conducted in 2014 subjects from the general population of a Northern Italian town. 6 More recently, in a large cohort of 3266 Caucasians untreated and treated hypertensive patients, it was demonstrated that women with MetS had an increase in LVMH 2.7 by 17% compared to women without MetS. Less pronounced (10%), but equally significant, differences, were observed in men. 25 Our results are in agreement with these latter findings and provide new information, showing that LVM was higher in both men and women with MetS regardless of the methods of indexation for LVM. Moreover, although LVM became progressively greater with age and by increasing 24-h SBP, in both sexes the association we observed between LVM and MetS was significant in each tertile of age and in each tertile of 24-h SBP, in which our study population was divided (Figures 1 and 2) .
Our paper, being a clinical study with a crosssectional design, only permits us to advance hypotheses about the relationships of MetS with LVM.
Increased arterial stiffness, previously reported in hypertensive subject with MetS, 12, 31, 32 or non-haemodynamic factors, 14 may be responsible for the increased LVM observed in individuals with MetS. It is well known that insulin resistance and the accompanying compensatory hyperinsulinemia are the pathophysiological key features underlying MetS. 2, 12 Trophic effects of insulin on myocardial tissue in cell cultures and animal models have been demonstrated. 33 Moreover, in some, but not all, human studies, an association between insulin and LVM has been found. 34, 35 Other potential biologic mediators of LVH in subjects with MetS may be sympathetic activation, 36, 37 increased production of endothelin-1 38, 39 and of aldosterone, 40 reduced levels of natriuretic peptides 41 or certain hormones, such as angiotensin II and leptin, which are secreted by white adipose tissue. 42, 43 Further studies are needed to elucidate the potential explanations of increased LVM in hypertensive subjects with MetS. In the present study, we have demonstrated that, anyhow MetS intervenes in the cardiac remodelling, the pathophysiological mechanism underlying this process seems not to act in a significantly different way in the two sexes.
There are some potential limitations of our study. The cross-sectional design precluded assessment of the temporality of the observed associations and thus determination of causality.
Moreover, previous anti-hypertensive treatment that had been stopped may have affected the results because of the persisting influence on cardiac mass, even though patients' BP may have returned to control values. However, in the subset of hypertensive patients who had never pharmacologically treated we found results similar to those obtained in the whole population, with regard to LVM. Moreover, the greater LVM in patients with MetS was confirmed, also taking into account previous treatment in multivariate analyses.
Finally, patients with MetS were older and showed more elevated SBP, than those without MetS. These factors may partially explain the greater values of LVM found in subjects with MetS. However, the differences regarding LVM and prevalence of LVH remained significant after adjustment for these covariates.
In conclusion, our study, showing that LVM and the prevalence of LVH are increased in both men and women with MetS, supports the concept that in hypertensive patients MetS must be considered a dangerous condition for the heart in both sexes.
